A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer

Pharmacogenomics Journal

Volumn 11, Issue 6, 2011, Pages 437-443

  Ho Pun Cheung, A ^a,b   Assenat, E ^a   Bascoul Mollevi, C ^a   Bibeau, F ^a   Boissiere Michot F ^a   Thezenas, S ^a   Cellier, D ^b   Azria, D ^a   Rouanet, P ^a   Senesse, P ^a   Ychou, M ^a   Lopez Crapez, E ^a  

^a CENTRE VAL D AURELLE   (France)

^b Merck KGaA France   (France)

Author keywords

predictive marker; radiochemotherapy; rectal cancer; response to treatment; SNP

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADPRT GENE; ADULT; AGED; APE1 GENE; APOPTOSIS; ARTICLE; ATM GENE; BAX GENE; BCL2 GENE; CANCER STAGING; CASP10 GENE; CASP3 GENE; CASP8 GENE; CASP9 GENE; CCND1 GENE; CDKN1A GENE; CELL ACTIVITY; CELL PROLIFERATION; CHEK1 GENE; CHEK2 GENE; CHEMORADIOTHERAPY; CONTROLLED STUDY; CTNNB1 GENE; CYP1A1 GENE; DNA REPAIR; EGF GENE; EGFR GENE; ERBB2 GENE; ERCC1 GENE; ERCC2 GENE; ERCC4 GENE; ERCC5 GENE; FCGR2A GENE; FCGR3A GENE; FEMALE; FGF2 GENE; FGFR4 GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GPX1 GENE; GSK3B GENE; GSTP1 GENE; GSTT1 GENE; HIF1A GENE; HUMAN; ICAM5 GENE; IGF1R GENE; IGF2R GENE; IL10 GENE; IL12 GENE; IL13 GENE; IL1B GENE; IL4 GENE; IL6 GENE; IL8 GENE; IMMUNE RESPONSE; LIG3 GENE; LIG4 GENE; LTA GENE; MAJOR CLINICAL STUDY; MALE; MBD4 GENE; MDM2 GENE; MGMT GENE; MLH1 GENE; MPO GENE; MT ND3 GENE; MTHFR GENE; NBN GENE; NFE2L2 GENE; NFKB1 GENE; NOS2A GENE; NOS3 GENE; OGG1 GENE; ONCOGENE; PARP 1 GENE; PPARG GENE; PREDICTIVE VALUE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PTGS2 GENE; RAD51 GENE; RAD52 GENE; RADIATION DOSE; RADIOSENSITIVITY; RECQL GENE; RECTUM CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SOD2 GENE; TGFB1 GENE; TNF GENE; TP53 GENE; TP53BP1 GENE; TP73 GENE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VEGFA GENE; XPA GENE; XRCC1 GENE; XRCC3 GENE; XRCC5 GENE; ZNF350 GENE;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; GENOTYPE; HUMANS; INTERLEUKIN-13; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECTAL NEOPLASMS; SUPEROXIDE DISMUTASE; TUMOR MARKERS, BIOLOGICAL;

EID: 81755163491     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.62     Document Type: Article

References (35)

1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
2. Sauer R. Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer. Pathol Oncol Res 2002; 8: 7-17. (Pubitemid 34532774)
3. Crane CH, Skibber JM, Feig BW, Vauthey J, Thames HD, Curley SA et al. Response to preoperative chemoradiation increases the use of sphincterpreserving surgery in patients with locally advanced low rectal carcinoma. Cancer 2003; 97: 517-524. (Pubitemid 36133820)
4. Gerard J, Chapet O, Nemoz C, Hartweig J, Romestaing P, Coquard R et al. Improved sphincter preservation in low rectal cancer with highdose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 2004; 22: 2404-2409. (Pubitemid 41115397)
5. Ruo L, Tickoo S, Klimstra D, Minsky B, Saltz L, Mazumdar M et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236: 75-81. (Pubitemid 34686453)
6. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-8696. (Pubitemid 46211512)
7. Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99-107.
8. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 2006; 32: 55-64. (Pubitemid 43103989)
9. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009; 74: 673-688.
10. Spindler KG, Nielsen JN, Lindebjerg J, Jakobsen A. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum 2007; 50: 1363-1369. (Pubitemid 47472390)
11. Grube D. Constants and variables in immunohistochemistry. Arch Histol Cytol 2004; 67: 115-134. (Pubitemid 39264548)
12. The International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.
13. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3: 912-920. (Pubitemid 37500176)
14. Robert J, Morvan VL, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005; 54: 171-196. (Pubitemid 40693684)
15. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23. (Pubitemid 27138353)
16. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006; 34: D617-D621.
17. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644-645. (Pubitemid 46522604)
18. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445. (Pubitemid 37033947)
19. Wright S. Adjusted p-values for simultaneous inference. Biometrics 1992; 48: 1005-1013. (Pubitemid 23066474)
20. Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 2007; 297: 489-498. (Pubitemid 46220804)
21. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 2005; 59: 143-148. (Pubitemid 40603325)
22. Wang CY, Mayo MW, Baldwin AS. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science 1996; 274: 784-787. (Pubitemid 26398259)
23. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003; 22: 5813-5827. (Pubitemid 37176702)
24. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson0s disease. Biochem Biophys Res Commun 1996; 226: 561-565. (Pubitemid 26331940)
25. Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005; 15: 311-319. (Pubitemid 40676552)
26. Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of antitumor immunity and tumor growth. Cancer Immunol Immunother 2004; 53: 79-85. (Pubitemid 38161213)
27. Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA. Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 2008; 57: 907-912.
28. Cameron L, Webster RB, Strempel JM, Kiesler P, Kabesch M, Ramachandran H et al. Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C4T, a polymorphism associated with allergic inflammation. J Immunol 2006; 177: 8633-8642. (Pubitemid 44893827)
29. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63: 655-666. (Pubitemid 41400049)
30. Ménard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008; 57: 1579-1587.
31. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129.
32. Ho-Pun-Cheung A, Assenat E, Thezenas S, Bibeau F, Rouanet P, Azria D et al. Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1094-1101. (Pubitemid 47053951)
33. Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR et al. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol 2009; 27: 1592-1599.
34. Wu X, Gu J, Wu T, Swisher SG, Liao Z, Correa AM et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24: 3789-3798. (Pubitemid 46628477)
35. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007; 56: 281-288. (Pubitemid 46590484)